Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics
- PMID: 35977245
- PMCID: PMC9206190
- DOI: 10.1001/jamahealthforum.2022.1435
Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics
Abstract
This cross-sectional study assesses pharmacy participation in the 340B Drug Pricing Program following the 2010 expansion and the extent to which growth has occurred in socioeconomically disadvantaged neighborhoods.
Copyright 2022 Lin JK et al. JAMA Health Forum.
Conflict of interest statement
Conflict of Interest Disclosures: Dr Li reported personal fees from HealthStatistics LLC and Covia Health Solutions outside the submitted work. Dr Doshi reported grants from Humana, Janssen, Merck, Novartis, PAN Foundation, Regeneron, and Sanofi, and personal fees from AbbVie, Acadia, Boehringer Ingelheim, Catabasis, Janssen, MeiraGTx, Merck, Otsuka, SAGE Therapeutics, Takeda, and The Medicines Company, all unrelated to and outside the submitted work. No other disclosures were reported.
Figures
References
-
- Notice regarding 340B drug pricing program-contract pharmacy services. Fed Regist. 2010;75(43):10272-10279. Accessed May 9, 2022. https://www.govinfo.gov/app/details/FR-2010-03-05/2010-4755/summary
